Targets › CAV1
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Sep 2027.
May act as a scaffolding protein within caveolar membranes. Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. (UniProt, Q03135)
Open in Phaseline: the race on CAV1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rein Therapeutics | LTI-03 Caveolin-1-scaffolding-protein-derived peptide | CAV1 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Sep 2027 |
Idiopathic Pulmonary Fibrosis (IPF) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.